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ABSTRACT 
BACKGROUND: Recent work has shown loss of phosphodiesterase 10A levels in middle-
stage and advanced treated patients with Parkinson’s disease, which was associated with 
motor symptom severity.  
OBJECTIVE: To assess phosphodiesterase 10A levels in early Parkinson’s disease, and 
compare with loss of dopamine transporter as markers of disease burden.  
METHODS: Seventy-eight subjects were included in this study (17 early de novo,15 early 
levodopa-treated,24 moderate-advanced levodopa-treated patients with Parkinson’s disease, 
and 22 healthy controls). All participants underwent [11C]IMA107 PET, [11C]PE2I PET and 
3-Tesla MRI scan.  
RESULTS: Early de novo Parkinson’s disease patients showed loss of [11C]IMA107 and of 
[11C]PE2I binding in caudate and putamen (P<0.001); early levodopa-treated Parkinson’s 
disease patients showed additional loss of [11C]IMA107 in the caudate (P<0.001; annual 
decline 3.6%) and putamen (P<0.001; annual decline 2.8%) but loss of [11C]PE2I only in the 
putamen (P<0.001; annual decline 6.8%). Lower [11C]IMA107 correlated with lower 
[11C]PE2I in the caudate (rho=0.51; P<0.01) and putamen (rho=0.53; P<0.01). Longer 
disease duration correlated with lower [11C]IMA107 in the caudate (rho=-0.72; P<0.001) and 
putamen (rho=-0.48; P<0.01), and with lower [11C]PE2I  only in the putamen (rho=-0.65; 
P<0.001). Higher burden of motor symptoms correlated with lower [11C]IMA107  in the 
caudate (rho=-0.42; P<0.05) and putamen (rho=-0.41; P<0.05), and with lower [11C]PE2I  
only in the putamen (rho=-0.69; P<0.001). 
CONCLUSION: Our findings demonstrate loss of phosphodiesterase 10A levels very early 
in the course of Parkinson’s disease and is associated with the gradual and progressive 
increase of motor symptoms. Phosphodiesterase 10A imaging shows similar potential with 
dopamine transporter imaging to follow disease progression.   
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INTRODUCTION 
Previous PET imaging studies have shown that changes in the molecular binding profile of 
selected brain targets may serve as promising markers of disease burden and progression, 
drug target identification and treatment response in therapeutic trials in patients with 
Parkinson’s disease 1. Loss of dopamine transporter (DAT) signal in Parkinson’s disease 
patients reflects loss of nigrostriatal dopamine neurons, and is typically associated with 
dopaminergic pathology in the putamen and the motor features of bradykinesia and rigidity 2. 
Phosphodiesterase 10A (PDE10A) is a striatal enzyme expressed in the axons of the medium 
spiny neurons, where it hydrolyses cAMP and cGMP 3, 4. In the striatal pathways, PDE10A 
plays a pivotal role in the regulation of dopaminergic signalling 5 and of several other brain 
functions, ranging from ion conductance to synaptic plasticity 6. Small pilot studies have 
shown loss of PDE10A levels in the caudate of Parkinson’s disease patients, but not in the 
putamen 7, 8. Our previous work with PET molecular imaging has demonstrated loss of 
PDE10A levels in the caudate, putamen and globus pallidus in moderate to advanced 
levodopa-treated patients with Parkinson’s disease, which was associated with motor 
symptoms and complications 9. Therefore, PDE10A, as an enzyme regulating striatal output 
and dopaminergic signalling, shows promise to serve as a marker of disease burden in 
patients with early Parkinson’s disease. However, it is unknown whether PDE10A is 
implicated at the earlier stages of the disease and how its biomarker value compares with the 
gold standard DAT molecular imaging.  
 
Here, we used PET with [11C]IMA107 to assess PDE10A levels and [11C]PE2I to compare 
DAT with PDE10A levels, and to explore for associations with clinical markers of disease 
burden in patients with early Parkinson’s disease including those who have never been 
treated with dopaminergic medications. We also compared [11C]IMA107 binding in our early 
population with data from moderate-advanced patients with Parkinson’s disease, performed 
previously  9. 
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METHODS 
Participants and clinical characteristics 
We studied a total of 78 subjects (56 patients with Parkinson’s disease and 22 healthy 
controls). Parkinson’s patients included 17 early de novo, 15 early levodopa-treated, and 24 
moderate-advanced levodopa-treated. While the latter group (n=24) came out of our previous 
study 9, we enrolled an additional 60 participants recruited from specialist Movement 
Disorders clinics at King’s College Hospital, National Hospital of Neurology and 
Neurosurgery, Imperial College NHS Trust and through public advertisement, of which 54 
subjects completed the study and were included in the analyses (Table 1).  
 
We included 32 patients with idiopathic Parkinson’s disease according to the Queen Square 
Brain Bank criteria, and 22 age- and gender-matched healthy individuals with no history of 
neurological or psychiatric disorders, who served as the control group (healthy controls). 
Parkinson’s disease patients included 17 subjects with a recent diagnosis (duration of 
symptoms ≤24 months) who were naïve to treatment for Parkinson’s symptoms (de novo), 
and 15 patients with early Parkinson’s disease (duration of symptoms ≤60 months) who were 
recently treated with levodopa (duration of treatment ≤24 months) and had no motor 
complications (early levodopa-treated). To get a full picture of changes in PDE10A binding 
at different stages of PD progression, we compared [11C]IMA107 binding in our early 
population with data from moderate-advanced patients with Parkinson’s disease. Population 
of moderate-advanced Parkinson’s disease were recruited previously 9 and included 24 
patients who had a mean disease duration of 7-13 years and were treated with levodopa for at 
least 24 months (moderate-advanced levodopa-treated). None of the Parkinson’s disease 
patients fulfilled the diagnostic criteria for Parkinson’s disease mild cognitive impairment 10 
or dementia 11 or depression 12, had any history of other neurological or psychiatric disorders, 
and were not under treatment with substances with known actions in PDEs (e.g. apremilast, 
cilomilast, luteolin, piclamilast, roflumilast and ibudilast). None of the Parkinson’s disease 
patients included had a diagnosis of scan without evidence of dopaminergic deficit (SWEDD) 
after [11C]PE2I PET scan. 
 
The group of early levodopa-treated and moderate-advanced levodopa-treated PD patients 
were on stable levodopa treatment for at least 6 months at the time of study enrolment. Daily 
dopaminergic medication dose was calculated with a formula based on the theoretical 
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equivalence to levodopa 9. Motor symptom severity was assessed with the MDS-UPDRS 
part-III and staged with Hoehn and Yahr scale in the practically defined off-medication state 
(after 12 hours overnight withdrawal of patient’s dopaminergic medications). MDS-UPDRS-
III subscores for rigidity, bradykinesia, tremor and axial symptoms were calculated as 
previously described9. Quality of life was measured with the 39-item Parkinson’s Disease 
Questionnaire. Neuropsychiatric symptoms were assessed with the Beck Depression 
Inventory second edition and the Hamilton Depression Rating Scale. Mini-Mental Status 
Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess 
general cognitive status. Disability was assessed by Modified Schwab and England Activities 
of Daily Living Scale. Non-Motor Symptoms Scale  for Parkinson’s disease was used to 
assess non-motor symptoms. Sleep disturbances were assessed with the Parkinson’s Disease 
Sleep Scale and the Epworth Sleepiness Scale 13. 
 
The study was approved by the institutional review boards and the research ethics committee. 
Written informed consent was obtained from all study participants in accordance with the 
Declaration of Helsinki. 
  
Scanning procedures 
All participants were screened successfully to undertake PET with [11C]IMA107 and 
[11C]PE2I, and one 3-Tesla MRI scanning under standard criteria (http://www.mrisafety.com; 
https://www.gov.uk/government/publications/arsac-notes-for-guidance). PET and MR 
imaging have been performed at Invicro London, UK. All participants were scanned on 
Siemens Biograph Hi-Rez 6 PET-CT scanner (Erlangen, Germany). A median dose of 297.15 
(interquartile range 276.1 to 307.8) MBq [11C]IMA107 [median mass injected: 3.3 ug 
(interquartile range 2.5 to 4.2)] was administered intravenously as a slow bolus injection over 
20s. A median dose of 320.3 (interquartile range 315.2 to 340.2) MBq [11C]PE2I [mean mass 
injected: 4.4 ug (interquartile range 3.7 to 5.8)] was administered intravenously as a bolus 
injection over 10s followed by a 10 ml saline bolus injection over 10s. [11C]IMA107 and 
[11C]PE2I have been performed on the same day after withholding consumption of 
caffeinated beverages for 12 hours 14. The group of early levodopa-treated and moderate-
advanced levodopa-treated PD patients undertake the scan in the on-medication state. 
 
Dynamic emission data were acquired continuously for 90 minutes following the injection of 
[11C]IMA107 and [11C]PE2I. The dynamic images were reconstructed into 26 frames (8 x 15 
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s, 3 x 60 s, 5 x 120 s, 5 x 300 s, and 5 x 600 s), using a filtered back projection algorithm 
(direct inversion Fourier transform) with a 128 matrix, zoom of 2.6 producing images with 
isotropic voxel size of 2 x 2 x 2 mm3, and smoothed with a transaxial Gaussian filter of 5 
mm. MRI scans were acquired with a 32-channel head coil on a 3-Tesla MRI Siemens 
Magnetom TrioTim syngo MR B17 (Erlangen, Germany) scanner, and included a T1-
weighted magnetization prepared rapid gradient echo sequence [MPRAGE; time repetition 
(TR) = 2300 ms, time echo (TE) = 2.98 ms, flip angle of 9°, time to inversion (TI) = 900 ms, 
matrix = 240 x 256] for co-registration with the PET images; fast grey matter T1 inversion 
recovery (FGATIR; repetition time = 3000 ms, echo time = 2.96 ms, flip angle of 8, time to 
inversion = 409 ms, matrix = 240 x 256)15 sequences for delineation of regions-of-interest. 
All MRI sequences used a 1 mm3 voxel size, anteroposterior phase encoding direction, and a 
symmetric echo. 
 
Imaging data analysis 
MRI-based volumetric analysis 
Because PDE10A is an intracellular enzyme mainly expressed in the basal ganglia nuclei 3, 4, 
degeneration of these nuclei may affect the levels of the enzyme. Thus, we investigated 
volumetric changes in subcortical nuclei in our cohort of Parkinson’s disease patients. We 
used the FreeSurfer image analysis suite (version 5.3.0 http://surfer.nmr.mgh.harvard.edu) to 
process individual MRI scans for deriving measures of subcortical volumes, as described 
before9. 
 
[11C]IMA107 and [11C]PE2I PET data analysis 
The Molecular Imaging and Kinetic Analysis Toolbox software package (MIAKATTM: 
www.miakat.org), implemented in MATLAB® (The Mathworks, Natick, MA, USA) was 
used to carry out image processing and kinetic modelling. MIAKAT™ combines in-house 
code with wrappers for FMRIB Software Library (FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) 
and Statistical Parametric Mapping (SPM, http://www.fil.ion.ucl.ac.uk/spm/) commands in 
order to provide state-of-the-art functionality within a coherent analysis framework. We 
followed the MIAKAT™ processing pipeline, ensuring that all quality control steps were 
completed to generate parametric images and regional estimates of [11C]IMA107 and 
[11C]PE2I non-displaceable binding potential (BPND). BPND were generated using a basis 
function implementation of the simplified reference tissue model, with the cerebellum as the 
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reference tissue for non-specific binding. Individual PET frames were corrected for head 
motion using frame-by-frame rigid registration using a frame with high signal-to-noise ratio 
as reference. PET images were co-registered to the corresponding MPRAGE MRI. 
 
Region of interest-based analysis 
To facilitate anatomical delineation of regions of interest, PET images were anatomically co-
registered and re-sliced to the corresponding volumetric structural T1-weighted MRI images 
in Statistical Parametric Mapping version12 (SPM12) software package implemented in 
Matlab 2015a. Regions of interest were delineated manually on the T1 co-registered FGATIR 
MRI sequence using ANALYZE version 12.0 (Mayo Foundation) medical imaging software 
package by two assessors (G.P. and H.W.) who were blinded to groups allocation, using used 
a reliable, robust and repeatable technique for manual delineation of basal ganglia structures 
16. Regions of interest included caudate, putamen, whole striatum (combination of caudate 
and putamen), ventral striatum, globus pallidus (external and internal segments), substantia 
nigra and motor thalamic nuclei. These brain regions express PDE10A to a varying degree 4, 
17. 
 
Voxel-based analysis 
Parametric images of [11C]IMA107 and [11C]PE2I BPND were spatially normalized into the 
T1-weighted MNI 152 template using the individual MRI with the Mutual Information 
Registration algorithm in SPM12. Parametric images were computed using appropriately 
weighted contrasts to localize significant decreases in mean voxel PET values after applying 
the Basal Ganglia Human Area Template 18. This masking reduces the number of voxel-by-
voxel statistical comparisons, and a cluster-corrected threshold of P<0.05 used to test for 
statistically significant effects. The contrasts were used to derive Z-scores on a voxel basis 
using the general linear model. The threshold for statistical significance was set to P<0.05 
after family wise error (FWE) correction for multiple comparisons. Voxel-wise statistics for 
between-group comparisons were performed by using SPM12 software package implemented 
in Matlab 2015a. 
 
Statistical analysis 
Statistical analysis and graph illustration were performed with SPSS (version 22) and 
GraphPad Prism (version 6.0c) for Windows 10, respectively.  
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For all variables, Gaussianity was tested with Shapiro-Wilk test and we proceeded with 
parametric tests for normally distributed variables and non-parametric tests for non-normally 
distributed variables. Multivariate analysis of variance (MANOVA) was used to assess the 
main effects of regional [11C]IMA107 and [11C]PE2I BPND among the groups. If the overall 
multivariate test was significant, P-values for each variable were calculated following 
Bonferroni’s multiple comparisons test. We interrogated correlations between PET and 
clinical data using Pearson r (normally distributed variables) or Spearman rho (non-normally 
distributed variables) and we applied Benjamini-Hochberg correction to reduce false 
discovery rate 19. We set the false discovery rate cut-off at 0.05. All data are presented as 
mean ± standard deviation, and the level α was set for all comparisons at P<0.05, corrected. 
 
RESULTS 
Volumetric analysis 
FreeSurfer analysis showed no subcortical volumetric differences in the caudate, putamen, 
ventral striatum, globus pallidus, and thalamus  between the groups of early de novo and 
early levodopa-treated Parkinson’s disease patients and healthy controls (Supplementary 
Table 1). 
 
Region of interest-based [11C]IMA107 BPND analysis in early de novo Parkinson’s disease 
patients 
Early de novo patients with Parkinson’s disease had lower mean [11C]IMA107 BPND values in 
whole striatum (ES=2.69, P<0.001), caudate (ES=3.75, P<0.001), putamen (ES=1.64, 
P<0.001) and ventral striatum (ES=1.21, P<0.05) compared to healthy controls (Figure 1A 
and 1B). There were no differences in mean [11C]IMA107 BPND values between early de 
novo Parkinson’s disease patients and healthy controls in globus pallidus internal (ES=0.54, 
P>0.10), globus pallidus external (ES=0.58, P>0.10), substantia nigra (ES=0.48, P>0.10) and 
motor thalamic nuclei (ES=0.28, P>0.10).  
 
Region of interest-based [11C]PE2I BPND analysis in early de novo Parkinson’s disease 
patients 
Early de novo patients with Parkinson’s disease had lower mean [11C]PE2I BPND values in 
whole striatum (ES=3.49, P<0.001), caudate (ES=1.53, P<0.05), putamen (ES=4.32, 
P<0.001), ventral striatum (ES=1.73, P<0.05), globus pallidus internal (ES=1.62, P<0.001), 
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globus pallidus external (ES=1.81, P<0.001) and substantia nigra (ES=1.67, P<0.001) 
compared to healthy controls (Figure 2A and 2B). There were no differences in mean 
[11C]PE2I BPND values between early de novo Parkinson’s disease patients and healthy 
controls in motor thalamic nuclei (ES=0.28, P>0.10). 
 
Effect of lateralisation in [11C]IMA107 BPND and [11C]PE2I BPND 
In the group of early de novo patients with Parkinson’s disease with unilateral motor 
symptoms, we assessed whether the clinically affected side of the body was associated with 
greater decreases in contralateral brain regions of interest [11C]IMA107 BPND and [
11C]PE2I 
BPND values. We found no differences in [
11C]IMA107 BPND values in any of the regions of 
interest between the most and less affected side; whereas [11C]PE2I BPND values in caudate 
(P<0.001), putamen (P<0.001), ventral striatum (P<0.001), globus pallidus internal 
(P<0.001), globus pallidus external (P<0.001) and substantia nigra (P<0.001) were decreased 
in the contralateral to most affected compared to the less affected side of the body (Figure 
2C).  
 
[11C]IMA107 BPND and [11C]PE2I BPND in levodopa-treated Parkinson’s disease patients 
Compared to early de novo Parkinson’s disease patients, early levodopa-treated patients with 
Parkinson’s disease had three years longer disease duration and showed additional 
[11C]IMA107 BPND loss of 17.2% (SD: 8.4%) in the caudate (P<0.001) and 9.5% (SD: 9.6%) 
in the putamen (P<0.001) (Figure 1A and 1B). Early levodopa-treated Parkinson’s disease 
patients showed additional [11C]PE2I BPND loss of was 34.7% (SD: 17%) in the putamen 
(P<0.001), whereas changes were not significant in the caudate, compared to early de novo 
Parkinson’s disease patients (Figure 2A and 2B). Compared to early de novo Parkinson’s 
disease patients, moderate-advanced patients further showed [11C]IMA107 BPND loss of 
13.2% (SD: 7.6%) in the caudate (P<0.001), 6.5% (SD: 5.6%) in the putamen (P<0.001) and 
of 10.2% (SD: 9.2%) in the globus pallidus internal (P<0.05). 
 
Voxel-Based [11C]IMA107 BPND and[11C]PE2I BPND analyses  
Voxel-by-voxel analysis of [11C]IMA107 and [11C]PE2I parametric BPND images between 
the groups of patients with Parkinson’s disease and healthy controls confirmed results 
obtained with region of interest analysis. SPM analysis within the striatal mask localized 
clusters of [11C]IMA107 BPND decreases in the right and left caudate (P<0.001) and right and 
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left putamen (P<0.001), and clusters of [11C]PE2I BPND decreases in the right and left 
caudate (P<0.05) and right and left putamen (P<0.001) in the early de novo Parkinson’s 
disease patients compared with the group of healthy controls. SPM analysis within the striatal 
mask localized clusters of [11C]IMA107 BPND decreases in right and left caudate (P<0.05) 
and right and left putamen (P<0.05), and clusters of [11C]PE2I BPND decreases in the right 
and left putamen (P<0.05) in the early levodopa-treated compared to early de novo patients 
with Parkinson’s disease. 
 
Head-to-head comparison between [11C]IMA107 BPND and [11C]PE2I BPND 
We compared loss of [11C]IMA107 BPND with loss of [
11C]PE2I BPND in each region of 
interest in Parkinson’s disease patients relative to normality data from the group of healthy 
controls. We found that loss of [11C]IMA107 BPND was greater than loss of [
11C]PE2I BPND 
in the caudate (P<0.01) but lower in the putamen (P<0.001), globus pallidus internal 
(P<0.01), globus pallidus external (P<0.001) and substantia nigra (P<0.01), and no different 
in ventral striatum (P>0.10) and motor thalamic nuclei (P>0.10) in early de novo Parkinson’s 
disease patients. Similarly, we found that loss of [11C]IMA107 BPND was greater than loss of 
[11C]PE2I BPND in the caudate (P<0.01) but lower in the putamen (P<0.001), globus pallidus 
internal (P<0.05), globus pallidus external (P<0.01) and substantia nigra (P<0.05), and no 
different in ventral striatum (P>0.10) and motor thalamic nuclei (P>0.10) in early levodopa-
treated Parkinson’s disease patients.  
 
We also evaluated the coefficient of variance (COV% = SD/mean *100) for [11C]IMA107 
and [11C]PE2I BPND. In early de novo Parkinson’s disease patients: (a) [11C]IMA107 BPND 
COV% was 9% in the whole striatum, 14% in the caudate, 8% in the putamen, 18% in the 
ventral striatum, 10% in the globus pallidus internal, 11% in the globus pallidus external, 
11% in substantia nigra, and 16% in the motor thalamic nuclei; (b) [11C]PE2I BPND COV% 
was 19% in the whole striatum, 21% in the caudate, 26% in the putamen, 22% in the ventral 
striatum, 29% in the globus pallidus internal, 26% in the globus pallidus external, 16% in the 
substantia nigra, and 11% in the motor thalamic nuclei. 
 
In early levodopa-treated Parkinson’s disease patients: (a) [11C]IMA107 BPND COV% was 
9% in the whole striatum, 10% in the caudate, 11% in the putamen, 18% in the ventral 
striatum, 15% in the globus pallidus internal, 13% in the globus pallidus external, 20% in 
substantia nigra, and 17% in the motor thalamic nuclei; (b) [11C]PE2I BPND COV% was 21% 
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in the whole striatum, 25% in the caudate, 26% in the putamen, 24% in the ventral striatum, 
30% in the globus pallidus internal, 27% in the globus pallidus external, 14% in the 
substantia nigra, and 12% in the motor thalamic nuclei. 
 
Correlations between [11C]IMA107 BPND and[11C]PE2I BPND in Parkinson’s disease 
patients 
Lower individual [11C]IMA107BPND values correlated with lower individual [
11C]PE2I BPND 
values in the caudate (rho=0.51; P<0.01) and putamen (rho=0.53; P<0.01), but not in ventral 
striatum (rho=0.013; P>0.10), globus pallidus internal (rho=0.21; P>0.10), globus pallidus 
external (rho=0.46; P>0.05), substantia nigra (rho=0.15; P>0.10) or motor thalamic nuclei 
(rho=0.15; P>0.10) in Parkinson’s disease patients (Figure 2D).  
 
Correlations between PET data and measures of Parkinson’s disease burden  
Parkinson’s disease patients had increased MDS-UPDRS-III (P<0.001), Non-motor 
Symptoms Scale (P<0.05), Beck Depression Inventory-II (P<0.05), and Hamilton Depression 
Rating Scale (P<0.05) scores, and worse 39-item Parkinson's disease Questionnaire (P<0.05) 
and Parkinson's Disease Sleep Scale (P<0.05) scores compared to healthy controls (Table 1). 
Only one early de novo Parkinson’s disease patient was treated also with selective serotonin 
reuptake inhibitors. As the cohorts were carefully matched for age, we found no effect of age 
in [11C]IMA107 and [11C]PE2I BPND in all regions-of-interest across all cohorts (P>0.10).  
No correlations were found between cognitive status (MMSE, MoCA), depression (Beck 
Depression Inventory-II, Hamilton Depression Rating Scale), 39-item Parkinson's disease 
Questionnaire, Parkinson's Disease Sleep Scale and [11C]IMA107 or [11C]PE2I BPND in any 
area.  
 
Longer Parkinson’s disease duration correlated with lower [11C]IMA107 BPND in the caudate 
(rho=-0.72; P<0.001) and putamen (rho=-0.48; P<0.01). Higher MDS-UPDRS-III total 
scores correlated with lower [11C]IMA107 BPND in the caudate (rho=-0.42; P<0.05) and 
putamen (rho=-0.41; P<0.05). Higher MDS-UPDRS-III rigidity scores correlated with lower 
[11C]IMA107 BPND in the caudate (rho=-0.52; P<0.01) and putamen (rho=-0.43; P<0.05). 
Higher MDS-UPDRS-III bradykinesia scores correlated with lower [11C]IMA107 BPND in 
the caudate (rho=-0.45; P<0.01) and putamen (rho=-0.47; P<0.01; Figure 3A). 
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Longer Parkinson’s disease duration correlated with lower [11C]PE2I BPND only in the 
putamen (rho=-0.65; P<0.001). Higher MDS-UPDRS-III total scores correlated with lower 
[11C]PE2I BPND only in the putamen (rho=-0.69; P<0.001). Higher MDS-UPDRS-III rigidity 
scores correlated with lower [11C]PE2I BPND only in the putamen (rho=-0.62; P<0.001). 
Higher MDS-UPDRS-III bradykinesia scores correlated with lower [11C]PE2I BPND only in 
the putamen (rho=-0.49; P<0.01; Figure 3B). 
 
Correlations between PET data, levodopa equivalent daily dosage and 
antidepressants 
In early treated PD patients, we investigated correlations between [11C]IMA107 or [11C]PE2I 
BPND and levodopa equivalent daily dosage. No correlations were found between LEDD and 
[11C]IMA107 or [11C]PE2I BPND in any area ([
11C]IMA107: whole striatum, rho=-0.27; 
P>0.10;  caudate, rho=-0.28; P>0.10;  putamen, rho=-0.32; P>0.10;  ventral striatum, rho=-
0.28; P>0.10;  globus pallidus internal, rho=-0.45; P=0.095;  globus pallidus external, rho=-
0.39; P>0.10;  substantia nigra, rho=-0.45; P=0.089;  motor thalamic nuclei, rho=-0.64; 
P=0.091 - [11C]PE2I: whole striatum, rho=-0.13; P>0.10;  caudate, rho=-0.28; P>0.10;  
putamen, rho=-0.12; P>0.10;  ventral striatum, rho=-0.01; P>0.10;  globus pallidus internal, 
rho=-0.32; P>0.10;  globus pallidus external, rho=-0.33; P>0.10;  substantia nigra, rho=-0.49; 
P=0.063;  motor thalamic nuclei, rho=-0.22; P>0.10). 
We could not investigate correlations between [11C]IMA107 or [11C]PE2I BPND and 
antidepressants (e.g. selective serotonin reuptake inhibitors or tricyclic antidepressants) 
because we had only one patient treated with selective serotonin reuptake inhibitors. 
 
DISCUSSION 
Our findings demonstrate that loss of striatal PDE10A levels is an early phenomenon in the 
course of Parkinson’s disease and is associated with duration and severity of motor 
symptoms. Our study translates into humans’ previous experimental work, which has 
demonstrated that lesions of nigrostriatal projections with 6-hydroxydopamine, induce a 
downregulation of PDE10A levels in the striatum in rodent models of Parkinson’s disease 20, 
21. 
 
We used PET molecular imaging to quantify PDE10A and DAT levels in the same cohorts of 
Parkinson’s disease patients and healthy controls. In both early de novo and early levodopa-
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treated patients with Parkinson’s disease both PDE10A and DAT levels were decreased in the 
striatum, and DAT also decreased in globus pallidus and substantia nigra. Our early de novo 
cohort of Parkinson’s disease patients had less than two year of disease duration and the 
cohort of early levodopa-treated less than five year of Parkinson’s symptoms and were taking 
levodopa for less than two years. Previously, we have reported loss of striatal PDE10A levels 
and correlations with the burden of motor symptoms and complications in middle-stage 
treated Parkinson’s disease patients with a mean of 7 years of disease duration and advanced 
treated Parkinson’s disease patients with a mean of 13 years of disease duration 9. We 
compared the levels of PDE10A in this population of moderate-advanced Parkinson’s disease 
patients with our group of early de novo. We found in the advanced stages of Parkinson’s 
disease further loss of PDE10A in the striatum and in the globus pallidus internal. 
Collectively, our data suggest that loss of striatal PDE10A levels appears early in the course 
of Parkinson’s disease and progresses over time, and is associated with the gradual increase 
of motor symptom burden in different disease stages. Our findings suggest that loss of 
PDE10A levels in globus pallidus is a phenomenon appearing later in the disease as PDE10A 
levels in this region was not affected in the earlier cohorts. Our findings were not affected by 
volumetric changes in the brain, age or gender that were also confirmed at a voxel level for 
the striatum.  
 
Loss of PDE10A correlated with loss of DAT in the striatum in early de novo and early 
levodopa-treated patients with Parkinson’s disease, suggesting an association between 
PDE10A and dopaminergic function. PDE10A plays a key role in the regulation of 
dopaminergic signalling and is essential for dopamine neurotransmission through the 
interaction with cAMP and the activation of Protein kinase A /dopamine- and cAMP-
regulated neuronal phosphoprotein 32 downstream cascade in striatal pathways 5, 6, 22. 
We did not find differences in PDE10A in the substantia nigra in our populations, which 
could be due to the power of resolution of PET in this area and the relatively lower 
expression of PDE10A compared to the striatum. 
 
We attempted to understand how informative PET molecular imaging of PDE10A and DAT 
could be for monitoring the disease progression, speculating on our cross-sectional data. Our 
levodopa-treated patients with Parkinson’s disease had three years longer disease duration 
compared to early de novo Parkinson’s disease patients. PDE10A levels showed further 
decline in both the caudate and putamen, whereas DAT levels was further reduced only in the 
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putamen in early levodopa-treated compared to early de novo Parkinson’s disease patients. 
PDE10A showed lower variability over the time, with a SD of 8.4% in the caudate and 9.6% 
in the putamen, whereas DAT showed a 17% SD in the putamen. This trend of reduction was 
consistent in the middle and advanced stages of the disease, where the PDE10A loss extended 
also to the pallidus. In our study we have shown that standardized differences (Cohen’s d) 
between early de novo and levodopa-treated with three-year longer disease duration are 1.48 
for caudate measured with [11C]IMA107, and 1.57 for putamen measured with [11C]PE2I. 
The greater loss of [11C]IMA107 in the caudate compared to the putamen might be simply 
due to the greater physiological levels of this protein in the caudate than putamen 4, 5. This 
has also implication for future clinical trials using [11C]IMA107 and [11C]PE2I PET imaging 
as biomarkers of disease progression. Assuming in detecting a 50% reduction in these 
differences in a potential 18-month clinical trial testing a disease modifying drug that reduces 
disease progression by 50%, we will have a 0.74 Cohen's d for caudate PDE10A and a 0.78 
for putamen DAT. These figures are greater than [18F]FDOPA, a validated biomarker of 
Parkinson’s progression, that showed Cohen’s d of 0.79 at three-year follow-up in early de 
novo patients with Parkinson’s 23, thus having a 0.39 Cohen's d in this hypothetical trial. 
Providing a 80% power with a two-sided test using 5% type I error rate, we may need 60 
participants if we use as endpoint the changes in the caudate [11C]IMA107 levels, 54 subjects 
if we use as endpoint the changes in the putamen [11C]PE2I levels and 200 subjects if we use 
as endpoint the changes in the putamen [18F]FDOPA levels. This suggests a similar strength 
for [11C]IMA107-PDE10A and [11C]PE2I-DAT over aromatic L-amino acid decarboxylase-
[18F]FDOPA as biomarkers for clinical trials. VMAT2 assessed with 
[11C]dihydrotetrabenazine ([11C]DTBZ) PET has also been suggested as a robust marker of 
Parkinson’s progression and would be interesting to see how this is compared to PDE10A 
PET  24. 
 
We performed head-to-head comparisons between loss of PDE10A and DAT in Parkinson’s 
disease patients relative to normality data from the group of healthy controls. We found that 
loss of PDE10A was greater than loss of DAT in the caudate, but lower in the putamen, 
globus pallidus and substantia nigra in both early de novo and early levodopa-treated patients 
with Parkinson’s disease. In early de novo and levodopa-treated patients with Parkinson’s 
disease, PDE10A tracer showed a 10% lower COV variability in the striatum, caudate and 
putamen compared to DAT. This could suggest that PDE10A is a more stable biomarker but 
also that PDE10A may have a lower sensitivity to dopaminergic disease process or that the 
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greater COV for DAT may simply reflect that it is a better marker of primary disease 
pathology in Parkinson’s disease; imperfect correlations between DAT and PDE10A would 
be compatible with related but different pathology. Loss of PDE10A in both the caudate and 
putamen, and loss of DAT only in the putamen correlated with longer Parkinson’s duration, 
total burden of motor symptoms, and with increased rigidity and bradykinesia. The level of 
correlations between PDE10A and DAT and clinical scales were similar. However, 
correlations with disease duration and with motor symptoms for PDE10A have lower 
regression (rho) values for both caudate and putamen than corresponding values for DAT in 
the putamen. We also found higher z-scores for DAT imaging at voxel-level compared to 
PDE10A, which further suggests that [11C]PE2I-DAT might have higher sensitivity 
compared to [11C]IMA107-PDE10A.  
 
Considering the underlying pathophysiology of Parkinson’s disease includes progressive 
deposition of α-synuclein, the ideal neuroimaging biomarker to monitor disease progression 
should be able to quantify regional deposition of abnormal α-synuclein accumulation. 
Development of such a molecular imaging radiotracer has been the focus of much research 
but is not yet forthcoming and assessment of DAT represents the most direct approach able to 
quantify presynaptic nigrostriatal dopaminergic neurons.  However, within the postsynaptic 
striatal neurons, cAMP signalling is finely regulated by the PDE10A. Lesions in nigrostriatal 
dopaminergic projections in animal models of Parkinson’s disease leads to an increase in 
cAMP levels, which could be due to a reduction in PDE10A levels/activity, and treatment 
with levodopa reduces the high cAMP levels observed in the denervated striatum 21, 25. 
Altered striatal second messenger signalling may be due to the lost ability of striatal neurons 
to induce both depotentiation and long-term depression 25. Hence, stimulation of postsynaptic 
striatal neurons from damaged dopaminergic terminals would fail, and dysregulation of 
PDE10A could be a pathogenic mechanism underlying the dysfunction of second messenger 
signalling. This enzyme might be the final regulator of striatal output and modulating its level 
crucial for the control of fine-tuned movements.  
 
We demonstrated a bilateral loss of PDE10A in the striatum (with no lateralization) at the 
early stages of Parkinson’s disease, when loss of DAT was only unilateral. This suggests that 
dysregulation of postsynaptic PDE10A might happen earlier than dopaminergic terminals 
loss and quite far from the motor onset of Parkinson’s disease. As confirmation of this theory, 
an early involvement of PDE10A has been previously demonstrated in pre-symptomatic 
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Huntington’s disease gene carriers 26, 27. However, one concern with PDE10-targeting tracers 
is that they may be modulated by drugs that do not directly target the PDE enzyme, either 
through direct or allosteric competition via altered cyclic nucleotide levels, or by drug-
induced changes in PDE10 levels, independently of the disease state 28. Thus, the use of 
[11C]IMA107 PET imaging as an outcome in clinical trials should be considered with caution 
in treated subjects. 
 
To minimize the variability over time, we decided to perform [11C]IMA107 and [11C]PE2I 
PET scans on the same day. However, in the levodopa-treated group, we had to perform the 
scan in the on-medication state, because the patients were not able to tolerate a whole day 
off-medication. Although this could induce a potential bias, because we are not able to 
exclude the possibility of an acute effect of dopaminergic medication on PDE10A levels, all 
our patients were on the same medication regimen for at least 6 months and we included the 
levodopa equivalent daily dose as covariate. We found no correlations between levodopa 
equivalent daily dose and PDE10A or DAT levels in any brain areas. Moreover, PDE10A 
levels were reduced in a population of PD patients who were never treated with any 
dopaminergic drugs, suggesting that reduction of PDE10A is probably not influenced by the 
dopaminergic treatment. We had no power to investigate the influence of other drugs on 
PDE10A levels. Based on our findings, we do not expect PDE10A levels to be vulnerable to 
dopamine medications. However, only acute challenge studies with [11C]IMA107 PET 
imaging performed before and after the drug administration could clarify this issue entirely. 
 
PDE10A imaging could be a robust alternative to DAT imaging regarding diagnosis and for 
evaluating disease burden and progression. We found a gradual progressive decline of 
PDE10A in Parkinson’s from very early to advanced stages. This makes PDE10A imaging 
potentially attractive to explore its clinical use further. It is important to note that both 
[11C]IMA107 and [11C]PE2I are kinetically well-behaved tracers with good-to-very good 
reproducibility 29, and the differences in their binding in the striatum are probably related to 
the pathological processes underlying Parkinson’s disease, more than characteristics of the 
tracers. A combined approach using both radiotracers may be useful because of their 
sensitivity to different underlying pathological processes. Despite these potential advantages 
of PDE10A imaging, only PET ligands are currently available for PDE10A whereas DAT 
levels can be measured with SPECT imaging. This limitation reduces the cost-effective use of 
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this novel molecular imaging technique until a SPECT PDE10A tracer becomes available. 
Neither DAT or PDE10A are good biomarkers for other Parkinson’s symptoms, like tremor 
or depression, where other mechanisms, such as serotonergic transporter deficit, seems to 
have a prominent role 30-33. 
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FIGURE LEGENDS 
Figure 1. (A) Altered PDE10A expression in anatomically defined brain regions of 
Parkinson’s disease patients. Axial, sagittal and coronal (MNI co-ordinates: x = 19, y = −8, 
z = 4) mean summed PET images derived from (top) 22 healthy controls, (middle) 17 
Parkinson’s disease early de novo and (bottom) Parkinson’s disease early levodopa-treated 
patients in stereotaxic space showing progressive loss of [11C]IMA107 BPND in PD. Colour 
bar reflects range of [11C]IMA107 BPND intensity. (B) PDE10A expression in the groups of 
Parkinson’s disease patients and healthy controls. Column bar graphs showing mean 
[11C]IMA107 BPND in subcortical brain regions in Parkinson’s disease early de novo patients, 
Parkinson’s disease early levodopa-treated patients and healthy controls. *P <0.05, 
**P <0.01, ***P <0.001.    
Figure 2. (A) Altered DAT expression in anatomically defined brain regions of 
Parkinson’s disease patients. Axial, sagittal and coronal (MNI co-ordinates: x = 19, y = −8, 
z = 4) mean summed PET images derived from (top) 22 healthy controls, (middle) 17 
Parkinson’s disease early de novo and (bottom) Parkinson’s disease early levodopa-treated 
patients in stereotaxic space showing progressive loss of [11C]PE2I BPND in Parkinson’s 
disease. Colour bar reflects range of PET BPND intensity. (B) DAT expression in the groups 
of Parkinson’s disease patients and healthy controls. Column bar graphs showing mean 
[11C]PE2I BPND in subcortical brain regions in Parkinson’s disease early de novo patients, 
Parkinson’s disease early levodopa-treated patients and healthy controls. *P <0.05, 
**P <0.01, ***P <0.001.   (C) Laterality of mean loss of DAT expression in Parkinson’s 
disease patients. Axial, coronal and sagittal (MNI co-ordinates: x = 19, y = −8, z = 4) mean 
summed PET images derived from (top) most affected right and (bottom) left of Parkinson’s 
disease patients in stereotaxic space showing significant loss of [11C]PE2I BPND in the 
Parkinson’s disease patients. Colour bar reflects range of [11C]PE2I BPND intensity. (D) 
Correlations between PDE10A and DAT in Parkinson’s disease (PD) patients. 
Correlation between [11C]IMA107 and [11C]PE2I BPND (top) in the caudate (rho=0.514; 
P=0.003) and (bottom) in the putamen (rho=0.527; P=0.002). Parkinson’s disease early de 
novo in black circles and Parkinson’s disease early levodopa-treated in grey circles. 
Figure 3. Correlations between PDE10A and DAT in relation to motor symptoms in 
Parkinson’s disease patients. Correlation between disease duration (first line) and 
[11C]IMA107 BPND in the caudate (rho=-0.721; P<0.0001) and [
11C]IMA107 and [11C]PE2I 
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in the putamen (rho=-0.481; P=0.005 for [11C]IMA107 and rho=-0.645; P<0.0001 for 
[11C]PE2I). Correlation between MDS-UPDRS-III motor scores (second line) and 
[11C]IMA107 BPND in the caudate (rho=-0.423; P=0.016) and [
11C]IMA107 and [11C]PE2I in 
the putamen (rho=-0.410; P=0.020 for [11C]IMA107 and rho=-0.692; P<0.0001 for 
[11C]PE2I). Correlation between MDS-UPDRS-III rigidity subscores (third line) and 
[11C]IMA107 BPND in the caudate (rho=-0.515; P=0.003) and [
11C]IMA107 and [11C]PE2I in 
the putamen (rho=-0.432; P=0.014 for [11C]IMA107 and rho=-0.620; P<0.0001 for 
[11C]PE2I). Correlation between MDS-UPDRS-III bradykinesia subscores (forth line) and 
[11C]IMA107 BPND in caudate (rho=-0.448; P=0.010) and putamen (rho=-0.467 ; P=0.007 for 
[11C]IMA107 and rho=-0.493; P=0.005 for [11C]PE2I). Parkinson’s disease early de novo in 
black circles and Parkinson’s disease early levodopa-treated in grey circles.  
 
